Saturday, June 23

6:00 PM

Conference Registration

8:00 PM

Welcome Reception and Dinner

Sunday, June 24

8:00 AM

Breakfast

8:50 AM

Welcome and Opening Remarks

SESSION I

Molecular Mechanisms of Tumorigenesis

Chairs: Dimitris Mastellos and Ruben Pio

9:00 AM

1

Complement and humoral innate immunity in the regulation of cancer-related inflammation

Alberto Mantovani

9:20 AM

2

Role of the classical complement pathway in tumor progression

Marie Daugan, Remi Noe, FlorentPetitprez, Catherine Sautes-Fridman, Wolf Herman Fridman, and Lubka Roumenina

9:40 AM

3

C5a/C5aR in cancer progression and treatment

Ruben Pio

10:00 AM

4

Pro-tumoral role of Complement activation in murine sarcoma models

Sabrina Di Marco, Elena Magrini, Chiara Perucchini, Kevin Berthenet, Marialuisa Barbagallo, Andrea Ponzetta, Cecilia Garlanda, and Alberto Mantovani

10:15 AM

5

Complement C3a-C3aR axis and host microbiota in the development of colorectal cancer

Silvia Guglietta, Sara Carloni, Alice Bertocchi, Lukas Weber, Bruno Fosso, Graziano Pesole, Mark Robinson, and Maria Rescigno

10:30 AM

6

Complement system mutations in cancer: uncovering new relationships between tumor hypoxia and complement

Monica Olcina, Nikolas Balanis, Ryan Kim, Michael Thompson, Thomas Graeber, and Amato Giaccia

10:45 AM

Coffee Break and Poster Viewing

SESSION II

Therapeutic Development

Chairs: Anna Blom and Eleni Gavriilaki

11:25 AM

7

An update on the clinical development of compstatin (AMY-101)

John Lambris, Edimara Reis, Nadja Berger, Markus-Huber Lang, Bo Nilsson, Richard Smith, Yuzhou Zhang, Dimitrios Mastellos, Daniel Ricklin, Ali-Reza Biglarnia, George Hajishengallis, Periklis Foukas, Lorraine Rush, Elias Sayias, Margarita Nunez, Despina Yancopoulou, and Antonio Risitano

11:45 AM

8

Inhibition of complement alternative pathway by orally administered inhibitors of complement factor D

Mingjun Huang, Steven Podos, Wengang Yang, Manuel Galvan, Amanda Luu, Dharaben Patel, Jane Thanassi, Guangwei Yang, Yongsen Zhao, Hetal Kocinsky, Michael Geffner, Avner Ingerman, Avinash Phadke, and Jason Wiles

12:00 PM

9

Natural and engineered "Factor H"-based regulators: delineation of structure-function relationships for effective host cell protection in vitro and in vivo

Christoph Schmidt, Yuzhou Zhang, Annette Palmer, AdamKeenan, Arthur Dopler, Carla Nester, Markus Huber-Lang, and Richard Smith

12:20 PM

10

Differential effects of complement therapeutics in trauma- and sepsis-induced organ dysfunction

Markus Huber-Lang, R Neugebauer, S Chakraborty, E Karasu, and John Lambris

12:40 PM

11

Ecotin, a serine proteinase inhibitor from E. coli, is a potent complement-inhibiting factor

Dávid Szakács, Zoltán Nagy, Dávid Héja, Veronika Harmat, Gábor Oroszlán, József Dobó, Péter Gál, and Gábor Pál

1:55 PM

12

New analogs of the complement C3 inhibitor compstatin with increased solubility and improved pharmacokinetic profile

Nadja Berger, Tchilabalo Alayi, Ranillo Resuello, Joel Tuplano, Edimara Reis, and John Lambris

1:10 PM

13

Conferring latency upon a complement inhibitor using TGF-beta LAP

Laurence Towner, Eva-Maria Nichols, David Gould, and Yuti Chernajovsky

1:25 PM

14

Funding translational research and development of pharmaceutical innovation – sources and strategies to create novel therapeutics

Charles Baltic

1:45 PM

Lunch and Informal Discussions

7:30 PM

Dinner and Informal Discussions

Monday, June 25

8:00 AM

Breakfast

SESSION III

Mechanisms of Activation and Regulation

Chairs: Georgios Hajishengallis and Lubka Roumenina

9:00 AM

15

Regulating complement activation through Collectin-11

Steven Sacks

9:20 AM

16

Major complement evasion strategy, binding of complement inhibitors to Streptococcus pyogenes, and its relevance for therapy

Anna Blom, David Ermert, and Sanjay Ram

9:40 AM

17

Properdin: Research, clinical and diagnostic perspectives

Viviana Ferreira

10:00 AM

18

Anti-inflammatory and immunomodulatory actions of the complement inhibitor isoform C4BP(b-) in murine lupus nephritis

Ana Luque, Elia Ripoll, Inmaculada Serrano, Catarina Malta, Josep Grinyó, Joan Torras, and Josep Aran

10:15 AM

19

Potential of increased alternative pathway regulation by using complement regulator factor H potentiating antibody

Gillian Dekkers, Richard Pouw, Mieke Brouwer, Marlon de Gast, Anna van Beek, Pilar Sánchez-Corral, Lambertus van den Heuvel, Christoph Schmidt, Arie van der Ende, Diana Wouters, TacoKuijpers, Theo Rispens, and Ilse Jongerius

10:30 AM

20

Discovering a new role of an old friend. MASP-1 provides an unexpected link between the alternative and lectin pathways of complement

Andrea Kocsis, Katalin Paréj, Csenge Enyingi, Ráhel Dani, Gábor Oroszlán, László Beinrohr, József Dobó, Péter Závodszky, Gábor Pál, and Péter Gál

10:45 AM

21

Extensive basal level activation of the lectin pathway protease, MASP-3

Gábor Oroszlán, Ráhel Dani, András Szilágyi, Péter Závodszky, Steffen Thiel, Péter Gál, and József Dobó

11:00 AM

22

Functional cooperation between complement factor H and the long pentraxin PTX3 in the immune response to Aspergillus fumigatus

Raffaella Parente, Francesca Petroni, Marina Sironi, Roberto Leone, Sonia Valentino, Barbara Bottazzi, Alberto Mantovani, and Antonio Inforzato

11:15 AM

Coffee Break and Poster Viewing

SESSION IV

Structure and Hematological Disorders

Chairs: Daniel Ricklin and Antonio Risitano

12:00 PM

23

Molecular insight into the mode of action of the C3 inhibitor Cp40

Daniel Ricklin, Xiaoguang Xue, Didier Devaurs, Malvina Papanastasiou, Henri van Son, Georgia Sfyroera, Brigitte Fiege, Christina Lamers, Edimara Reis, Mark Moll, Lydia Kavraki, Piet Gros, John D. Lambris

12:20 PM

24

Structural insights into antibody-mediated complement activation by cryo-EM

Deniz Ugurlar, StuartHowes, Piet Gros, and Thomas Sharp

12:40 PM

25

A nanobody platform for structural and functional studies of the complement system

Henrik Pedersen, Alessandra Zarantonello, Rasmus Jensen, Rasmus Pihl, Trine Gadeberg, Kasper Andersen, Steffen Thiel, Nick Laursen, and Gregers Andersen

1:00 PM

26

Complement inhibition 2.0 for paroxysmal nocturnal hemoglobinuria

Antonio Risitano

1:20 PM

27

Clonal selection in paroxysmal nocturnal hemoglobinuria

Rodrigo Calado

1:40 PM

28

Role of IgM and complement in HIT immune pathogenesis

Sanjay Khandelwal, Sreenivasulu Gunti, Abner Notkins, and Gowthami Arepally

2:00 PM

29

Role of IgM and complement in immune activation against self-antigens in blood

Sanjay Khandelwal, Joann Ravi, John Lambris, Edimara Reis, Sreenivasulu Gunti, Abner Notkins, and Gowthami Arepally

2:15 PM

Lunch and Informal Discussions

7:30 PM

Dinner and Informal Discussions

Tuesday, June 26

8:00 AM

Breakfast

SESSION V

Complement in Immune Response and Development

Chairs: Viviana Ferreira and Steven Sacks

9:00 AM

30

Complement-targeted inhibition of periodontitis using derivatives of factor H

Xiaofei Li, Baomei Wang, Edimara Reis, Da-Yo Yuh, Christoph Schmidt, John Lambris, and George Hajishengallis

9:20 AM

31

Immune profile of non-human primates under prolonged C3 inhibition

Edimara S. Reis, Nadja Berger, Avneesh K. Gautam, Justin T. Gumas, Sophia Koutsogiannaki, Ranillo R.G. Resuello, Joel V. Tuplano, Bo Nilsson, Ali-Reza Biglarnia, Markus Huber-Lang, George Hajishengallis, John D. Lambris

9:40 AM

32

Hexamerization-enhanced CD37 and CD20 monoclonal antibodies synergize in complement-dependent cytoxicity (CDC) to kill patient-derived chronic lymphocytic leukemia (CLL) cells with unprecedented potency

Ronald Taylor, MargaretLindorfer, SimoneOostindie, Erika Cook, Clive Zent, Richard Burack, Frank Beurskens, Janine Schuurman, Esther Breij, and Paul Parren

10:00 AM

33

Phagocytosis of live and dead Escherichia coli and Staphylococcus aureus in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14

Erik Skjeflo, Dorte Christiansen, AnneLandsem, Jorgen Stenvik, Trent Woodruff, Terje Espevik, Erik Nielsen, and Tom Eirik Mollnes

10:20 AM

34

Novel roles of the complement during embryo development

Roberto Mayor

10:40 AM

35

C5aR1 and TLR2 interact and upregulate the immune cell recruiting and osteoclast-inducing factor CXCL10 in osteoblasts

Yvonne Mödinger, Anna Rapp, Julia Pazmandi, Anna Vikman, Markus Huber-Lang, and Anita Ignatius

10:55 AM

36

Sialylation of fetal tissue is essential to control complement balance during embryonic development

Markus Abeln, Samanta Cajic, Erdmann Rapp, Rita Gerardy-Schahn, AnjaMünster-Kühnel, and Birgit Weinhold

11:10 AM

Coffee Break and Poster Viewing

SESSION VI

Neurological and Coagulation Disorders

Chairs: Markus Huber-Lang and Trent Woodruff

11:50 AM

37

C3 blockade for ischemic and hemorrhagic stroke: Proposed phase I/IIa safety and preliminary efficacy trial.

Edward Sander Connolly

12:10 PM

38

Role of complement in brain dysfunction during sepsis

Peter Ward, Firas Zetoune, and Fatemeh Fattahi

12:30 PM

39

Is the complement C5a receptor 2 (C5aR2) a therapeutic target for neurodegenerative disease?

Trent Woodruff, Rui Li, Richard Gordon, and John Lee

12:50 PM

40

Successful eculizumab therapy for recurrent guillain barre syndrome caused by CD59 loss and protein-losing enteropathy caused by CD55 loss

Dror Mevorach

11:05 PM

41

Interactions between complement and coagulation in thromboinflammation

Bo Nilsson and Kristina Nilsson Ekdahl

1:25 PM

42

The lipid transporter ApoE is a potent complement inhibitor

Susanne Ackermann, Peter Zipfel, and Christine Skerka

1:45 PM

43

Cholesterol crystals induce coagulation that can be prevented by targeting complement

Anne Marie Rokstand, Caroline Gravastrand, Bente Halvorsen, BjørgSteinkjer, Mona Skjelland, Eva Jacobsen, John D. Lambris, Tom Eirik Mollnes, Ole-Lars Brekke, and Terje Espevik

2:00 PM

Lunch and Informal Discussions

3:30 PM

City Tour

7:30 PM

Dinner and Informal Discussions

Wednesday, June 27

8:00 AM

Breakfast

SESSION VII

Biomarkers and Diagnostics

Chairs: Carla Nester and Ronald Taylor

9:00 AM

44

Identifying genomic biomarkers of complications in solid-organ transplantation

Brendan Keating

9:20 AM

45

Comparative effects of sub-optimal sample handling on multiple complement measurements: Is there a potential signature of mishandling?

Cynthia Marschner, Thuy Ton, ThomasGalway, and Ashley Frazer-Abel

9:40 AM

46

Precision medicine for C3 glomerulopathy – identifying novel biomarkers

Richard Smith, Bertha Martin, GongXin Yu, Nicolo Ghiringhelli, Amanda Bierer, Yuzhou Zhang, and Carla Nester

10:00 AM

47

Longitudinal Biomarker Monitoring in Complement Mediated Kidney Disease

Carla Nester, Zhang Yuzhou, and Richard Smith

10:20 AM

48

Connecting genetic risk to hemolytic uremic syndrome through the new generation sequencing of complement genes

Véronique Fremeaux-Bacchi, Paula Viera-Martins, KhalilEl Karoui, Chantal Loirat, and Fadi Fakhouri

10:40 AM

49

CFHR gene variations provide insights into the pathogenesis of human kidney diseases: Hemolytic Uremic Syndrome and FHR-Glomerulonephritis

Thorsten Wiech, Christine Skerka, and Peter Zipfel

11:00 AM

Coffee Break and Poster Viewing

SESSION VIII

Kidney Diseases

Chairs: Veronique Fremeaux-Bacchi and Peter Zipfel

11:40 AM

50

Complement blockade for the prevention and treatment of antibody mediated rejection

Robert Montgomery

12:00 PM

51

Transplant-associated thrombotic microangiopathy: genetic susceptibility in adult hematopoietic cell transplant recipients

Eleni Gavriilaki, Tasoula Touloumenidou, Despina Mallouri, Ioannis Batsis, Anna Vardi, Anastasia Marvaki, Maria Koutra, Eudoxia-Evaggelia Koravou, Aggeliki Paleta, Apostolia Papalexandri, Panagiotis Tsirigotis, Ioanna Sakellari, and Achilles Anagnostopoulos

12:20 PM

52

Complement in the pathogenesis of non-autoimmune kidney disease

Joshua Thurman

12:40 PM

53

Characterization of humanized C3 mice as a potential model of C3 glomerulopathy

Kishor Devalaraja-Narashimha, Yifan Luo, Cong Huang, Theodore Kaplan, Scott MacDonnell, Rebecca Peyser, Gabor Halasz, Karoline Meagher, Sarah Casanova, John McWhirter, Michael Roos, William Poueymirou, William Olson, Lynn MacDonald, Brian Zambrowicz, Andrew Murphy, George Yancopoulos, and Lori Morton

1:55 PM

54

Inhibition of complement C5a Receptor 1 reduces renal inflammation and attenuates diabetic kidney disease

Sih Min Tan, Sally Penfold, Vicki Thallas-Bonke, Elif Ekinci, Trent Woodruff, and Melinda Coughlan

1:10 PM

Closing Remarks

1:30 PM

Lunch and Informal Discussions

8:00 PM

Farewell Dinner

Thursday, June 28

8:00 AM

Breakfast

Departure

POSTERS

55

Single nucleotide polymorphisms within Mucin-type O-glycan genes are associated with colorectal cancer survival

Shun Lu, Calogerina Catalano, Kari Hemminki, and Asta Försti

56

Risk adapted dose-intensified postoperative radiation therapy in thymomas patients using a simultaneous integrated boost technique applied with helical Tomotherapy

Yuan Qin, Shun Lu, and Jinyi Lang

57

Regulation of Selecin Levels by siRNA delivery vehicles

Mario Bandulik, Shashank Pinnapireddy, Patrick Schlote, Jens Schaefer, and Udo Bakowsky

58

The D121 nanobody – an inhibitor of the alternative pathway proconvertase assembly

Henrik Pedersen, Rasmus Jensen, Nick Laursen, and Gregers Andersen

59

Complement Fluid Phase Regulators in Head and Neck Squamous Cell Carcinoma

Ulrike Werner, Ralph Pries, and Barbara Wollenberg

60

A humanized antibody against the complement factor 3 neoantigen that can inhibit alternative complement activation: its preparation and properties

Alexander Ischenko, Alexander Trofimov, Valeria Sergeeva, Sergei Rodin, Alexei Gorbunov, Nathalia Pigareva, and Alexander Petrov

61

Assessing C3 deposition and complement regulation on the cell surface in aHUS

Yuzhou Zhang, Margaret Lindorfer, Carla Nester, Ronald Taylor, and Richard Smith

62

Regional differences in terminal complement complex (TCC) deposition suggest a correlation with degenerative changes of intervertebral disc endplates

Graciosa Teixeira, Taryn Saggese, Zhiyao Yong, Amelie Kuhn, Raquel Goncalves, Michael Ruf, Uwe Mauer, Anita Ignatius, Rolf Brenner, and Cornelia Neidlinger-Wilke

63

Complement Receptor of the Immunoglobulin Superfamily (CRIg) inhibits progression of Non-alcoholic Steatohepatitis via Regulation of CD8+ T-cells

Janusz von Renesse, Ioannis Kourtzelis, Marina Nati, Iryna Pyrina, Ales Neuwirth, Antonios Chatzigeorgiou, and Triantafyllos Chavakis

64

Regulation of AMPK-dependent MDR1 expression by resveratrol in cisplatin-resistant human bladder cancer T24 cells via attenuating NF-κB and CRE transcriptional activity

Jin-Woo Jeong, Seung Young Lee, Hyun MiJin, Byung-GonRyu, Ji YoungJung, Hye Kyeong Kang, and Kyung MinChoi

65

Key role of the number of complement receptor 1 on erythrocytes for binding of Escherichia coli to erythrocytes and for leukocyte phagocytosis and oxidative burst in human whole blood

Ole Brekke, Dorte Christiansen, Aymric Kisserli, Hilde Fure, Jim Dahl, Brigitte Reveil, Béatrice Gay, Judith Ludviksen, Thierry Tabary, Tom Eirik Mollnes, and Jacques Cohen

66

A novel human whole blood model for the study of thrombin in complement activation and inflammation

Per Nilsson, Christina Johnson, Soeren Pischke, Hilde Fure, Anne Landsem, Grethe Bergseth, Linda Haugaard-Kedstrom, Markus Huber-Lang, Ole-Lars Brekke, and Tom Eirik Mollnes

67

Validation and feasibility of generating C5b6 neoepitope antibodies

Emily Dinley, Lasse Stach, Nadia Tournier, Ryan Bingham, Darren Gormley, Thil Batuwangala, Semra Kitchen, and Eva-Maria Nichols

68

Identification of follicular dendritic cells (FDCs) from human tonsils and binding of model complement complexes

Laura Rapley, Eleonora Lekova, Kiran Nistala, and Christian Ellson